Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Gilead Sciences Inc GILD

Healthcare Biotechnology
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, coronavirus disease 2019 (COVID-19) and cancer. It is focused on the discovery, development and commercialization of medicines in areas of unmet medical need. Its portfolio of marketed products... see more

Recent & Breaking News (NDAQ:GILD)

U.S. FDA Approves Yescarta® for Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic Therapy

Business Wire March 5, 2021

Gilead Sciences Completes Acquisition of MYR GmbH

Business Wire March 4, 2021

 Gilead to Present New Data at CROI 2021 Demonstrating the Company's Commitment to Addressing Urgent Global Health Needs

Business Wire March 2, 2021

Gilead Sciences to Present at Upcoming Investor Conferences

Business Wire February 18, 2021

The Benefits of Moringa Could be Used in the Pandemic Fight

Livemoney February 17, 2021

Gilead Sciences and Wake Forest University School of Divinity Partner to Address HIV Epidemic Through Faith-Based Programming and Community Outreach

Business Wire February 16, 2021

Kite Announces New ZUMA-1 Cohort Analysis Evaluating Prophylactic Corticosteroid Use With Yescarta® in Patients With Relapsed or Refractory Large B-cell lymphoma

Business Wire February 10, 2021

Kite Appoints Frank Neumann as Worldwide Head of Clinical Development

Business Wire February 8, 2021

Gilead Sciences Announces 4.4 Percent Increase in First Quarter 2021 Dividend

Business Wire February 4, 2021

Gilead Sciences Announces Fourth Quarter and Full Year 2020 Financial Results

Business Wire February 4, 2021

Moringa May be an Essential Tool in the Fight Against the Global Pandemic

Livemoney February 4, 2021

Gilead and the Human Rights Campaign Will Work Together to Combat HIV Epidemic and Promote Transgender Justice

Business Wire February 2, 2021

Gilead Sciences and Gritstone Announce Collaboration Utilizing Gritstone's Vaccine Platform Technology for HIV Cure

Business Wire February 1, 2021

Gilead Sciences to Release Fourth Quarter and Full Year 2020 Financial Results on Thursday, February 4, 2021

Business Wire January 21, 2021

Francesco M. Marincola Joins Kite as Worldwide Head of Cell Therapy Research

Business Wire January 19, 2021

Gilead and Vir Biotechnology Establish Clinical Collaboration to Explore Combination Strategies for Functional Cure for Chronic Hepatitis B Virus

GlobeNewswire January 12, 2021

Gilead Sciences Announces Updated 2020 Guidance

Business Wire January 11, 2021

Kite and Oxford BioTherapeutics Establish Cell Therapy Research Collaboration in Blood Cancers and Solid Tumors

Business Wire January 6, 2021

Gilead Sciences to Present at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021

Business Wire December 21, 2020

Kite's Tecartus(TM) (KTE-X19) Granted Conditional Marketing Authorization for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma in Europe

Business Wire December 16, 2020